Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Zenith Drugs Ltd is a pharmaceutical company specializing in manufacturing affordable, high-quality medicines. Their product range includes ORS powder, liquid orals, ointments, liquid externals, and capsules.
Incorporated in 2000, Zenith has swiftly progressed from a modest manufacturing house to a Schedule M and WHO GMP compliant facility, highlighting their commitment to quality.
The company has recently transitioned to a public limited entity, indicating strategic growth ambitions, underscored by an upcoming Initial Public Offering (IPO).
Over the years, Zenith has methodically expanded its product lines, demonstrating adaptability and a keen eye on market demands, expanding into new formulations and manufacturing capabilities.
The continuous expansion reflects a strategic intent to capture a broader market share, aligning product offerings with patient needs and market trends.
Pharmaceuticals & Biotechnology
Pharmaceuticals
78 Cr
High Risk
8.4
37.7
0.2
1.3
73.45
33.30
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Zenith Drugs Ltd (ZENITHDRUG) is currently trading at 48.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zenith Drugs Ltd is a pharmaceutical company specializing in manufacturing affordable, high-quality medicines. Their product range includes ORS powder, liquid orals, ointments, liquid externals, and capsules. Incorporated in 2000, Zenith has swiftly progressed from a modest manufacturing house to a Schedule M and WHO GMP compliant facility, highlighting their commitment to quality. The company has recently transitioned to a public limited entity, indicating strategic growth ambitions, underscored by an upcoming Initial Public Offering (IPO). Over the years, Zenith has methodically expanded its product lines, demonstrating adaptability and a keen eye on market demands, expanding into new formulations and manufacturing capabilities. The continuous expansion reflects a strategic intent to capture a broader market share, aligning product offerings with patient needs and market trends.
Over the past 52 weeks, Zenith Drugs Ltd has traded between a low of ₹33.30 and a high of ₹73.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zenith Drugs Ltd has a market capitalization of approximately 77.77. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zenith Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 77.77 Cr, Zenith Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zenith Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zenith Drugs Ltd is 8.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
8
Neutral
2
Bullish
4
Bearish
9
Neutral
2
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Bearish
8
Neutral
2
Bullish
4
Bearish
8
Neutral
2
Bullish
4
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
43.51 | 87 Cr | 7.62 | 1.08 | 1.15 | 14.17 | 19.07 | 13.18 | ||
76.00 | 81 Cr | 22.55 | 1.52 | 0.00 | 5.76 | 6.56 | 2.17 | ||
48.10 | 78 Cr | 8.35 | 1.25 | 0.00 | 15.41 | 18.92 | 6.93 | ||
37.09 | 71 Cr | 64.39 | 1.57 | 0.00 | 2.44 | 6.78 | 0.89 | ||
233.45 | 71 Cr | -32.27 | 1.05 | 0.00 | -4.86 | -2.57 | -1.78 | ||
109.75 | 68 Cr | 19.52 | 9.02 | 0.00 | — | — | 0.00 | ||
37.50 | 68 Cr | -324.24 | 1.23 | 0.00 | -0.39 | 1.12 | -0.22 | ||
| Median: 7 Co. | — | 48.10 | 71 Cr | 8.35 | 1.25 | 0.00 | 4.10 | 6.67 | 0.89 |
